PTCT
HealthcarePTC Therapeutics, Inc.
$64.22+0.86 (+1.36%)
Prev Close
$63.36
Open
$63.91
High
$65.78
Low
$63.80
Volume
387.4K
Market Cap
$5.63B
P/E
8.30
Div Yield
—
Over the past 12 months, insider activity at PTC Therapeutics, Inc. (PTCT) has been exclusively selling, with 0 insider purchases totaling $0.00 and 35 insider sales totaling $11.18M. The most recent insider transaction was by Okey Stephanie (director), who sold $980.0K worth of shares on Mar 12, 2026. PTC Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $5.63B.
Buys (12M)
0
$0.00
Sells (12M)
35
$11.18M
Net Activity
Net Seller
$11.18M
Active Insiders
10
last 12 mo
PTCT Price Chart
PTCT Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 12, 2026↗ | Okey Stephanie | director | Sell | 14,000 | $70.00 | $980.0K | 8,000 |
| Mar 9, 2026↗ | Almstead Neil Gregory | officer: CHIEF TECHNICAL OPS OFFICER | Sell | 3,989 | $63.38 | $252.8K | 2,737 |
| Mar 9, 2026↗ | Golden Lee Scott | officer: EVP & CHIEF MEDICAL OFFICER | Sell | 10,000 | $63.38 | $633.8K | 79,944 |
| Mar 9, 2026↗ | Okey Stephanie | director | Sell | 6,333 | $63.38 | $401.4K | 8,000 |
| Feb 23, 2026↗ | Boulding Mark Elliott | officer: EXEC. VP AND CLO | Sell | 3,019 | $69.48 | $209.8K | 107,643 |
| Feb 20, 2026↗ | Almstead Neil Gregory | officer: CHIEF TECHNICAL OPS OFFICER | Sell | 3,121 | $69.36 | $216.5K | 112,140 |
| Feb 20, 2026↗ | Golden Lee Scott | officer: EVP & CHIEF MEDICAL OFFICER | Sell | 2,484 | $69.36 | $172.3K | 89,944 |
| Feb 20, 2026↗ | Gravier Pierre | officer: CHIEF FINANCIAL OFFICER | Sell | 2,992 | $69.36 | $207.5K | 87,318 |
| Feb 20, 2026↗ | Klein Matthew B. | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 7,371 | $69.36 | $511.3K | 387,082 |
| Feb 20, 2026↗ | Pauwels Eric | officer: CHIEF BUSINESS OFFICER | Sell | 3,019 | $69.36 | $209.4K | 77,122 |
| Feb 20, 2026↗ | Utter Christine Marie | officer: SVP, CHIEF ACCOUNTING OFFICER | Sell | 2,494 | $69.36 | $173.0K | 70,199 |
| Feb 19, 2026↗ | Boulding Mark Elliott | officer: EXEC. VP AND CLO | Sell | 8,913 | $69.38 | $618.4K | 111,314 |
| Feb 18, 2026↗ | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 3,121 | $69.36 | $216.5K | 0 |
| Feb 18, 2026↗ | Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER | Sell | 2,484 | $69.36 | $172.3K | 0 |
| Feb 18, 2026↗ | Gravier Pierre | CHIEF FINANCIAL OFFICER | Sell | 2,992 | $69.36 | $207.5K | 0 |
| Feb 18, 2026↗ | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | Sell | 7,371 | $69.36 | $511.3K | 0 |
| Feb 18, 2026↗ | Pauwels Eric | CHIEF BUSINESS OFFICER | Sell | 3,019 | $69.36 | $209.4K | 0 |
| Feb 18, 2026↗ | Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER | Sell | 2,494 | $69.36 | $173.0K | 0 |
| Feb 17, 2026↗ | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 5,894 | $69.33 | $408.6K | 0 |
| Jan 12, 2026↗ | Almstead Neil Gregory | officer: CHIEF TECHNICAL OPS OFFICER | Sell | 940 | $76.45 | $71.9K | 115,196 |
| Jan 12, 2026↗ | Boulding Mark Elliott | officer: EXEC. VP AND CLO | Sell | 6,347 | $77.06 | $489.1K | 115,177 |
| Jan 12, 2026↗ | Golden Lee Scott | officer: EVP & CHIEF MEDICAL OFFICER | Sell | 866 | $76.45 | $66.2K | 92,428 |
| Jan 12, 2026↗ | Klein Matthew B. | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 2,514 | $76.45 | $192.2K | 394,453 |
| Jan 12, 2026↗ | Pauwels Eric | officer: CHIEF BUSINESS OFFICER | Sell | 7,348 | $77.02 | $565.9K | 84,928 |
| Jan 12, 2026↗ | Utter Christine Marie | officer: SVP, CHIEF ACCOUNTING OFFICER | Sell | 1,034 | $76.45 | $79.0K | 72,693 |
| Jan 8, 2026↗ | Almstead Neil Gregory | officer: CHIEF TECHNICAL OPS OFFICER | Sell | 2,411 | $77.19 | $186.1K | 117,103 |
| Jan 8, 2026↗ | Boulding Mark Elliott | officer: EXEC. VP AND CLO | Sell | 6,618 | $77.31 | $511.6K | 119,162 |
| Jan 8, 2026↗ | Golden Lee Scott | officer: EVP & CHIEF MEDICAL OFFICER | Sell | 1,982 | $77.12 | $152.9K | 93,936 |
| Jan 8, 2026↗ | Gravier Pierre | officer: CHIEF FINANCIAL OFFICER | Sell | 2,139 | $76.95 | $164.6K | 90,310 |
| Jan 8, 2026↗ | Klein Matthew B. | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 8,165 | $77.15 | $629.9K | 399,983 |
| Jan 8, 2026↗ | Pauwels Eric | officer: CHIEF BUSINESS OFFICER | Sell | 3,141 | $77.18 | $242.4K | 88,841 |
| Jan 8, 2026↗ | Utter Christine Marie | officer: SVP, CHIEF ACCOUNTING OFFICER | Sell | 2,616 | $77.19 | $201.9K | 74,962 |
| Jan 6, 2026↗ | Boulding Mark Elliott | officer: EXEC. VP AND CLO | Sell | 2,266 | $75.55 | $171.2K | 122,044 |
| Jan 6, 2026↗ | Reeve Emma | director | Sell | 734 | $76.00 | $55.8K | 10,666 |
| Jan 6, 2026↗ | STEELE GLENN JR MD PHD | director | Sell | 12,000 | $76.35 | $916.2K | 18,500 |
PTCT Insider Buying Activity
The following table shows recent insider purchases of PTC Therapeutics, Inc. (PTCT) stock reported via SEC Form 4 filings.
No insider buying activity found for PTCT in the last 12 months.
PTCT Insider Selling Activity
The following table shows recent insider sales of PTC Therapeutics, Inc. (PTCT) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 12, 2026↗ | Okey Stephanie | director | Sell | 14,000 | $70.00 | $980.0K | 8,000 |
| Mar 9, 2026↗ | Almstead Neil Gregory | officer: CHIEF TECHNICAL OPS OFFICER | Sell | 3,989 | $63.38 | $252.8K | 2,737 |
| Mar 9, 2026↗ | Golden Lee Scott | officer: EVP & CHIEF MEDICAL OFFICER | Sell | 10,000 | $63.38 | $633.8K | 79,944 |
| Mar 9, 2026↗ | Okey Stephanie | director | Sell | 6,333 | $63.38 | $401.4K | 8,000 |
| Feb 23, 2026↗ | Boulding Mark Elliott | officer: EXEC. VP AND CLO | Sell | 3,019 | $69.48 | $209.8K | 107,643 |
| Feb 20, 2026↗ | Almstead Neil Gregory | officer: CHIEF TECHNICAL OPS OFFICER | Sell | 3,121 | $69.36 | $216.5K | 112,140 |
| Feb 20, 2026↗ | Golden Lee Scott | officer: EVP & CHIEF MEDICAL OFFICER | Sell | 2,484 | $69.36 | $172.3K | 89,944 |
| Feb 20, 2026↗ | Gravier Pierre | officer: CHIEF FINANCIAL OFFICER | Sell | 2,992 | $69.36 | $207.5K | 87,318 |
| Feb 20, 2026↗ | Klein Matthew B. | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 7,371 | $69.36 | $511.3K | 387,082 |
| Feb 20, 2026↗ | Pauwels Eric | officer: CHIEF BUSINESS OFFICER | Sell | 3,019 | $69.36 | $209.4K | 77,122 |
| Feb 20, 2026↗ | Utter Christine Marie | officer: SVP, CHIEF ACCOUNTING OFFICER | Sell | 2,494 | $69.36 | $173.0K | 70,199 |
| Feb 19, 2026↗ | Boulding Mark Elliott | officer: EXEC. VP AND CLO | Sell | 8,913 | $69.38 | $618.4K | 111,314 |
| Feb 18, 2026↗ | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 3,121 | $69.36 | $216.5K | 0 |
| Feb 18, 2026↗ | Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER | Sell | 2,484 | $69.36 | $172.3K | 0 |
| Feb 18, 2026↗ | Gravier Pierre | CHIEF FINANCIAL OFFICER | Sell | 2,992 | $69.36 | $207.5K | 0 |
| Feb 18, 2026↗ | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | Sell | 7,371 | $69.36 | $511.3K | 0 |
| Feb 18, 2026↗ | Pauwels Eric | CHIEF BUSINESS OFFICER | Sell | 3,019 | $69.36 | $209.4K | 0 |
| Feb 18, 2026↗ | Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER | Sell | 2,494 | $69.36 | $173.0K | 0 |
| Feb 17, 2026↗ | Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 5,894 | $69.33 | $408.6K | 0 |
| Jan 12, 2026↗ | Almstead Neil Gregory | officer: CHIEF TECHNICAL OPS OFFICER | Sell | 940 | $76.45 | $71.9K | 115,196 |
| Jan 12, 2026↗ | Boulding Mark Elliott | officer: EXEC. VP AND CLO | Sell | 6,347 | $77.06 | $489.1K | 115,177 |
| Jan 12, 2026↗ | Golden Lee Scott | officer: EVP & CHIEF MEDICAL OFFICER | Sell | 866 | $76.45 | $66.2K | 92,428 |
| Jan 12, 2026↗ | Klein Matthew B. | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 2,514 | $76.45 | $192.2K | 394,453 |
| Jan 12, 2026↗ | Pauwels Eric | officer: CHIEF BUSINESS OFFICER | Sell | 7,348 | $77.02 | $565.9K | 84,928 |
| Jan 12, 2026↗ | Utter Christine Marie | officer: SVP, CHIEF ACCOUNTING OFFICER | Sell | 1,034 | $76.45 | $79.0K | 72,693 |
| Jan 8, 2026↗ | Almstead Neil Gregory | officer: CHIEF TECHNICAL OPS OFFICER | Sell | 2,411 | $77.19 | $186.1K | 117,103 |
| Jan 8, 2026↗ | Boulding Mark Elliott | officer: EXEC. VP AND CLO | Sell | 6,618 | $77.31 | $511.6K | 119,162 |
| Jan 8, 2026↗ | Golden Lee Scott | officer: EVP & CHIEF MEDICAL OFFICER | Sell | 1,982 | $77.12 | $152.9K | 93,936 |
| Jan 8, 2026↗ | Gravier Pierre | officer: CHIEF FINANCIAL OFFICER | Sell | 2,139 | $76.95 | $164.6K | 90,310 |
| Jan 8, 2026↗ | Klein Matthew B. | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 8,165 | $77.15 | $629.9K | 399,983 |
| Jan 8, 2026↗ | Pauwels Eric | officer: CHIEF BUSINESS OFFICER | Sell | 3,141 | $77.18 | $242.4K | 88,841 |
| Jan 8, 2026↗ | Utter Christine Marie | officer: SVP, CHIEF ACCOUNTING OFFICER | Sell | 2,616 | $77.19 | $201.9K | 74,962 |
| Jan 6, 2026↗ | Boulding Mark Elliott | officer: EXEC. VP AND CLO | Sell | 2,266 | $75.55 | $171.2K | 122,044 |
| Jan 6, 2026↗ | Reeve Emma | director | Sell | 734 | $76.00 | $55.8K | 10,666 |
| Jan 6, 2026↗ | STEELE GLENN JR MD PHD | director | Sell | 12,000 | $76.35 | $916.2K | 18,500 |
PTCT Insiders
Similar Stocks to PTCT
VRTX
Vertex Pharmaceuticals Incorporated
$470.20-1.66%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$743.51-0.41%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$313.45-1.19%
$42.07B
INSM
Insmed Incorporated
$139.06-0.33%
$30.07B
UTHR
United Therapeutics Corporation
$538.00+0.97%
$21.50B
INCY
Incyte Corporation
$92.25+0.27%
$20.10B
RVMD
Revolution Medicines, Inc.
$95.44+0.39%
$20.10B
MRNA
Moderna, Inc.
$52.38-1.89%
$19.96B